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Abstract Soluble CD44standard (sCD44s) and CD44v6
(sCD44v6) cannot only be detected in sera of patients with
pancreatic carcinoma but also of healthy blood donors. To
investigate whether sCD44s and sCD44v6 are derived from white
blood cells, we stimulated whole blood with phytohemagglutinin
and interleukin-2, which induced expression of CD44v6 only on
monocytes. For further investigations, we used the promyelocytic
leukemia cell line Hl-60. Only Hl-60 cells differentiating along
the macrophage pathway showed increased expression of CD44s
and CD44v6. Furthermore, only macrophages showed increased
secretion of sCD44s and sCD44v6. Our data suggest that CD44s
and CD44v6 are common adhesion molecules on macrophages
and macrophage-like cells. ß 2000 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
CD44 is a cell surface proteoglycan expressed on a variety
of cell types, including peripheral blood (PB) T and B lym-
phocytes, monocytes [1^4], Langerhans cells and dendritic
cells [5,6]. CD44 has been shown to bind hyaluronan (HA)
[3,4], ¢bronectin [5], MIP-1L [6] and MHC class II invariant
chain [7]. There is evidence for a role of CD44 as a receptor
which mediates binding of mononuclear and epithelial cells to
extracellular matrix ligands such as hyaluronic acid, ¢bronec-
tin and collagen [3,7,8]. Following cell activation, the intra-
cellular domain of surface CD44 undergoes phosphorylation
[9], palmitoylation [10] and cytoskeletal binding [11,12], and
possesses GTPase activity [13]. An in vitro role for CD44 has
been demonstrated in T lymphocyte activation [10,14^20], NK
target lysis [21], B cell lymphopoiesis [22] and cell^cell adhe-
sion [15,23^26]. Human serum is able to induce binding of
HA to PB monocytes, but not to T and B lymphocytes, and
upregulate monocyte expression of high molecular weight
CD44v isoforms [27].
The CD44 gene, located on chromosome 11, consists of at
least 19 exons. Ten of which encode the standard form of
CD44. Alternative splicing of the pre-mRNA leads to nine
high molecular weight isoforms of CD44 (CD44v2^v10). In
humans, CD44v1 seems to be non-functional because of a
stop codon [10]. The CD44v6 splice variant of the transmem-
brane receptor family of CD44 was ¢rst isolated and cloned
from a rat pancreatic carcinoma cell line and has been shown
to confer metastatic behavior to non-metastatic tumor cells
[28]. CD44v6 is suggested to be a prognostic factor in many
human malignancies including breast, gastric and colorectal
cancer [29^31]. Furthermore, CD44v6 expression in non-small
cell lung cancer [32] and gastric cancer [33] is supposed to
contribute to a high metastatic potential and CD44v6 anti-
sense inhibits metastases in the metastatic colorectal tumor
cell line HT29 [34]. We could recently show that CD44v6 is
expressed in both, normal pancreas and pancreatic cancer
[35], and that, interestingly, soluble CD44standard (sCD44s)
and CD44v6 (sCD44v6) are signi¢cantly reduced in pancreatic
carcinoma patients compared to healthy volunteers [36].
There, immunoprecipitation of human sera with anti-
CD44v6 revealed three CD44v6 isoforms ranging between
90 kDa and 160 kDa, while in the supernatant of pancreatic
carcinoma cell lines, an isoform with 175 kDa could be de-
tected, which was abandoned in human sera of pancreatic
cancer patients which implies that PB leukocytes and not tu-
mor cells could be the source of sCD44v6.
The aim of this study was to determine CD44 isoform ex-
pression on PB monocytes and lymphocytes and the ability of
cultured mononuclear cells to upregulate CD44v6, under the
hypothesis that expression of CD44v6 enables extravasation
of cells into the tissue and that cancer cells mimic this natural
occurring macrophage function.
2. Materials and methods
2.1. Reagents
DMEM media and fetal calf serum were purchased from Biochrom
(Berlin, Germany). Phytohemagglutinin (PHA), interleukin-2 (Il-2),
dimethylsulfoxide (DMSO), phorbol 12-myristate 13-acetate (PMA)
and vitamin D3 were from Sigma (St. Louis, MO, USA). Q-Interferon
was purchased from R+D System (Wiesbaden, Germany). FITC-con-
jugated F(abP)2 goat anti-mouse Ig, PE-conjugated anti-CD3, anti-
CD56, anti-CD19 and anti-CD14 were from Dako Corp. (Hamburg,
Germany). Monoclonal control and mouse monoclonal antibody
(mAb) recognizing CD44 standard and CD44v6 were from Bender-
Medsystems (Vienna, Austria). Enzyme-linked immunosorbent assay
(ELISA) kits for the detection of soluble human standard CD44 and
CD44v6 were purchased from BenderMedsystems (Vienna, Austria).
2.2. Whole blood culture
Heparin-anticoagulated blood was cultured for 0 h, 24 h, 48 h and
72 h at 37‡C in 5% CO2 atmosphere in mitogen-containing lyophilized
culture medium (PHA 1 Wg/ml, Il-2 1000 U/ml) in glass vessels. After
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incubation, blood cells were harvested, adherent cells were collected
by vigorously shaking the vessel, red blood cells were lysed (Optilyse,
Immunotech, Germany) and leukocytes were washed twice with phos-
phate-bu¡ered saline (PBS). All experiments were replicated at least
three times.
2.3. Hl-60 cell culture
Hl-60 cells, obtained from American Type Culture Collection, were
cultured in DMEM media supplemented with 10% fetal calf serum.
For experiments, cells were seeded at 5U105 cells/ml and treated with
DMSO at a concentration of 1%, with PMA at doses of 1.5 nM, with
vitamin D3 at doses of 1 nM and Q-interferon with 250 U/ml. After
12, 24, 36, 48 h of treatment, cells were harvested, adherent cells were
harvested using Puck’s EDTA, supernatants collected and immedi-
ately frozen at 320‡C. Cells were washed twice with PBS. All experi-
ments were replicated at least three times.
2.4. Determination of cell viability
For determination of cell viability, cells were stained by trypan blue
(Sigma, St. Louis, MO, USA) and the numbers of viable and dead
cells were determined by light microscopy.
2.5. ELISA
Commercial ELISAs were used to measure levels of soluble CD44
standard and CD44v6 in media from Hl-60 cells exposed to DMSO,
PMA, vitamin D3 and Q-interferon as provided by the manufacturers.
A⁄nity-puri¢ed mAbs were used to capture and horseradish peroxi-
dase-conjugated mAbs were directed against circulating adhesion mol-
ecules for detection. Results were obtained in ng/ml on the basis of
four standards.
2.6. Immuno£uorescence staining and £ow cytometry
2.6.1. Whole blood cultures. Harvested cells were resuspended in
PBS at 5U106 cells/ml, and 100 Wl of each sample was incubated with
a mixture of human immunoglobulins (Pentaglobin, Biotest, Dreieich,
Germany) to block Fc-R. After 10 min of incubation, saturating con-
centrations of the following PE-labeled mAbs were added: CD3,
CD56, CD19 and CD14, followed by FITC-labeled mAbs CD44s
and CD44v6. PE-labeled and FITC-labeled mouse Ig served as neg-
ative control. After incubation for 30 min at 4‡C, samples were then
washed and immediately analyzed. Samples were examined in a £uo-
rescence-activated cell sorter (FACScan) £ow cytometer (Becton
Dickinson, Heidelberg, Germany) equipped with CellQuest software.
Cell surface expression of CD44s and CD44v6 on monocytes was
assayed in double labeling protocols gating on CD14 cells. Log for-
ward light scatter and log 90‡ light scatter were used to gate out
debris. 10 000 gated events were collected for each sample and plotted
on a three decade £uorescence scale.
2.6.2. Hl-60 cultures. After 12, 24, 36 and 48 h of treatment, cells
were harvested, washed twice with PBS and resuspended in PBS at
5U106 cells/ml. 100 Wl of each sample was incubated with a mixture
of human immunoglobulins (Pentaglobin, Biotest, Dreieich, Ger-
many) to block Fc-R. After 10 min of incubation, saturating concen-
trations of the unlabeled mAbs CD44s and CD44v6 or mouse Ig as
negative control were added for 30 min at 4‡C. Samples were then
washed and incubated with £uoresceinated goat anti-mouse secondary
antibody for 30 min, washed again and immediately analyzed. Cell
viability was determined by £ow cytometry using ethidium mono-
azide. Only viable cells were used for further £ow analysis.
2.7. Western blot analysis
Cells were lysed by sonication and then boiled in sodium dodecyl
sulfate (SDS) gel sample bu¡er for 5 min. 20 Wg of protein was
resolved electrophoretically on denaturing 10% polyacrylamide gels.
Proteins were transferred to nitrocellulose membranes (Schleicher and
Schu«ll, Dassel, Germany) using a transblot apparatus (Phase, Lu«beck,
Germany). Non-speci¢c interactions were blocked by preincubation of
the membranes with a milk powder suspension (10% dry milk in PBS).
Membranes were incubated at room temperature with the following
mAbs. Anti-CD44 standard and anti-CD44v6 (both BenderMedsys-
tems, Vienna, Austria). After speci¢c staining, membranes were incu-
bated with biotinylated rabbit anti-mouse polyclonal serum for 1 h
(Tropix, Bedford, MA, USA). After each antibody incubation, mem-
branes were washed with PBS containing 0.3% Tween 20 (Sigma).
Binding of antibodies was detected using Western-Light system (Tro-
pix).
2.8. Reverse transcription (RT)-PCR ampli¢cation and exon speci¢c
analysis
Total RNA was prepared from 1U106^5U106 cells as described
previously [32]. 5 Wl total RNA was mixed with diethylpyrocarbon-
ate-treated water, a CD44 speci¢c oligonucleotide at the 3P side of
constant exon 17 (C12A; 20 pmol) and 20 U RNasin (Stratagene,
Heidelberg, Germany). The mixture was incubated at 70‡C for
5 min; subsequently, dNTPs (¢nal concentration 1 mM), RT bu¡er,
dithiothreitol (5 mM) and 200 U Superscript Plus (Gibco BRL, Eg-
gerstein, Germany) were added to make a volume of 20 Wl. The
mixture was incubated at 37‡C for 1 h, followed by inactivation of
the enzyme at 95‡C for 5 min. For exon speci¢c PCR ampli¢cation,
primers were chosen at the 5P side of each variant exon using the
recently published oligonucleotides [32]. PCR reactions were per-
formed in a total volume of 20 Wl containing 50 mM KCl, 10 mM
Tris^HCl (pH 8.3), 1.5 mM MgCl2, 50 WM each dNTP, 5 pmol each
primer, 0.5 U Taq polymerase and 2 Wl cDNA. The cDNA was am-
pli¢ed in 35 cycles: 0.5 min denaturation at 95‡C; 1.5 min annealing
at 56‡C; and 1 min extension at 73‡C, followed by a ¢nal extension at
73‡C for 10 min. PCR products were analyzed on a 1.25% agarose gel
in 1UTris^borate EDTA. The ampli¢cation products were visualized
under UV light at 590 nm after staining of the gel with ethidium
bromide.
Fig. 1. Flow cytometric analysis of cell surface expression of CD44s
and CD44v6 on PB monocytes. Whole blood was cultured for 0 h,
24 h, 48 h and 72 h with PHA (1 Wg/ml), Il-2 (1000 U/ml) and
without treatment. Cells were harvested, erythrocytes were lysed and
cells were labeled with saturating amounts of FITC-conjugated anti-
CD44 and anti-CD44v6 followed by PE-conjugated mAb anti-
CD14. Cell surface expression of CD44s and CD44v6 on monocytes
was assayed in double labeling protocols gating on CD14 cells.
Values shown are averaged from ¢ve experiments. Results from
CD14 monocytes labeled with CD44v6 mAbs are grouped (A) and
monocytes labeled with CD44s mAbs are grouped (B).
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2.9. Statistical analysis
The statistical signi¢cance was evaluated by Student’s t test. Sig-
ni¢cant, when not speci¢cally indicated, refers to P6 0.05.
3. Results
3.1. E¡ect of PHA and Il-2 on cell surface expression of
CD44s and CD44v6 in PB lymphocytes and monocytes
Based upon previous ¢ndings that CD44v6 is transiently
expressed on B and T lymphocytes following antigenic stim-
ulation, we examined cell surface expression of CD44s and
CD44v6 on peripheral lymphocytes and monocytes under cul-
ture conditions that stimulate T cells. Cell surface expression
of CD44s and CD44v6 on PB monocytes was assayed in
double labeling protocols gating on CD14 cells. We could
observe signi¢cantly increased cell surface expression of
CD44s on PB monocytes cultured for 24 h and 48 h without
stimulation (P6 0.05) and 24 h after stimulation with PHA
(P6 0.05) (Fig. 1). CD44v6 on the cell surface of CD14
monocytes increased signi¢cantly (P6 0.05) after 24 h and
48 h without treatment, after 24 h stimulation with PHA
and after 24 h and 48 h stimulation with Il-2 compared
with fresh blood monocytes (Fig. 1). 48 h after stimulation
with PHA, there was a signi¢cant (P6 0.05) decrease of
Fig. 2. Morphological changes in Hl-60 cells exposed to PMA. PMA-treated cells changed from rounded to more spread compared to un-
treated control cells which remained round at any of the time points examined. 24 h after exposure to PMA, approximately 50% of the cells
adhere to the dish, followed by more than 75% adhesion at 48 h.
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CD44v6 compared to 24 h, whereas monocytes without mi-
togen showed a slight increase. It is well known that CD44v6
expression shows a peak 24^48 h following activation and a
decline to baseline levels thereafter. It could be possible that
monocytes without mitogen show the same kinetic later than
48 h of culture. Following in vitro culture of whole blood with
PHA and Il-2, there was no increase in cell surface expression
of CD44s and CD44v6 on T cells (CD3), natural killer cells
(CD56) or B cells (CD19) compared with fresh unstimulat-
ed lymphocytes (data not shown). To further investigate what
Fig. 3. Expression of CD44 and CD44v6 on the cell surface of Hl-60 cells as measured by £ow cytometry. Hl-60 cells were cultured in the pres-
ence or absence (control) of PMA for 0, 12, 24, 36 and 48 h. Cells were stained with primary antibodies against the human CD44s and
CD44v6 followed by FITC-labeled goat anti-mouse secondary antibody The gray line shows £uorescence at 0 h, the black line shows £uores-
cence at 12, 24, 36 and 48 h. Cells were analyzed by £ow cytometry. The y axis represents cell number, the x axis represents log £uorescence
intensity. Results were from one representative experiment; the pattern shown here was reproduced in ¢ve separate experiments.
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sort of white blood cells are able to express CD44s and
CD44v6, we used the promyelocytic leukemia cell line Hl-60
as a model of di¡erentiation.
3.2. E¡ect of DMSO, PMA, vitamin D3 and Q-interferon on
the morphology of Hl-60 cells
Hl-60 cells exposed to PMA exhibited a time course for
adhesion, with changes in morphology from rounded to
more spread. 12 h after exposure to PMA, 5^10% of the cells
had changed morphology, followed by approximately 50% of
the cells adhering to dishes by 24 h and more than 75% ad-
hesion at 36 h and 48 h. In contrast, cells without treatment
(control) or cells exposed to DMSO, vitamin D3 and Q-inter-
feron did not exhibit adhesive properties at any time points
examined, from 0 to 48 h. As shown in Fig. 2, cells treated
with PMA for 24 h or 48 h adhere to the cell culture dish
whereas untreated control cells remain rounded with no ad-
herence.
3.3. E¡ect of DMSO, PMA, vitamin D3 and Q-interferon on
cell surface expression of CD44s and CD44v6 in Hl-60
cells
The e¡ect of DMSO, PMA, vitamin D3 and Q-interferon
treatment of Hl-60 cells on expression of cell surface CD44s
and CD44v6 was determined by £ow cytometry. For di¡er-
entiation, we used experimental protocols known to induce
granulocyte, monocyte and macrophage di¡erentiation in
Hl-60 cells. Surface expression showed that more than 90%
of untreated Hl-60 cells constitutively expressed the standard
CD44 molecule. Intensity of £uorescence increased slightly
between 24 h and 48 h in cells exposed to DMSO, vitamin
D3 and Q-interferon. However, this increase did not reach
statistical signi¢cance. A much stronger upregulation was de-
tected upon treatment with PMA. Exposure of Hl-60 cells to
PMA resulted in an enhancement of CD44 standard protein
on the cell surface, which was observed as early as 24 h (Fig.
3).
Untreated cells at the time point 0 h expressed the epitope
encoded by exon v6 at low levels of about 8%. Hl-60 cells
without treatment and cells treated with DMSO, vitamin D3
and Q-interferon showed a slightly increased expression for
CD44v6 between 24 h and 36 h (data not shown). However,
Hl-60 cells di¡erentiating along the granulocyte and monocyte
pathway exhibited the same upregulation of CD44v6 like con-
trol cells. In contrast, exposure to PMA resulted in a much
stronger upregulation of CD44v6 much beyond that seen with
untreated cells or cells treated with DMSO, vitamin D3 or Q-
interferon. This strong increased expression for CD44v6 was
observed at 24 h and maintained throughout the time period
of this experiment. Compared to control levels, the addition
of PMA leads to an about 3-fold increased CD44v6 expres-
sion (Fig. 3).
3.4. E¡ect of DMSO, PMA, vitamin D3 and Q-interferon on
the amount of soluble CD44s and CD44v6 in cell culture
supernatant
To determine whether cells expressing CD44 standard and
CD44v6 were secreting these proteins, we determined the con-
centration of these proteins in media from Hl-60 cells exposed
to DMSO, PMA, vitamin D3 and Q-interferon at designated
time points using an ELISA method. Untreated cells as well
as cells treated with DMSO, PMA, vitamin D3 and interferon
induced the secretion of CD44 standard by Hl-60 cells. Mea-
surable levels of CD44 standard in media were noted by 0 h
and increased steadily up to 48 h. There were no di¡erences in
the amount of soluble CD44 standard in media of untreated
cells or Hl-60 cells treated with DMSO, vitamin D3 or Q-
interferon. As shown in Fig. 4, treatment with PMA induced
signi¢cantly increased secretion of CD44 standard into the
medium, compared to untreated control cells.
The same results were found with CD44v6. DMSO, vitamin
D3 and Q-interferon could not increase the amount of soluble
CD44v6 in the medium signi¢cantly, compared to untreated
control cells, whereas exposure to PMA resulted in a signi¢-
cantly increased secretion of CD44v6 into the medium (Fig.
4).
Fig. 4. CD44v6 and CD44s secretion in Hl-60 cells treated with
PMA and without treatment (control), as measured by ELISA. The
concentration of CD44v6 and CD44s was measured 0, 12, 24, 36
and 48 h after exposure in the medium. Results are expressed as ng/
ml. PMA led to an increased concentration of CD44v6 (group A)
in medium at time points of 12 h, 24 h, 36 h and 48 h (*P6 0.003
as compared to control) and to an increased concentration of CD44
standard (group B) in medium at time points of 24 h, 36 h and 48 h
(*P6 0.03 as compared to control).
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3.5. E¡ect of PMA on CD44 standard and CD44v6 measured
by Western blotting
To con¢rm the results of £ow cytometric analysis and ELI-
SA, we performed Western blot analysis on Hl-60 cells treated
with PMA or without treatment. Cell lysates were analyzed by
Western blotting using a CD44 antibody recognizing the stan-
dard form of CD44. A predominant CD44 protein of about
50 kDa was detected. CD44 standard was constitutively ex-
pressed on all cells independent of a given treatment. Western
blotting using a CD44v6 speci¢c antibody revealed a band at
97 kDa which was identi¢ed as CD44v6. As depicted in Fig.
5, untreated cells (control) expressed CD44v6 from 0 h up to
48 h. In vitro culture for 24 h in PMA induced increased
expression of CD44v6.
3.6. E¡ect of PMA treatment on CD44v mRNA expression in
Hl-60 cells
To examine the patterns of splice variants in the presence or
absence of PMA, total RNA was isolated, reverse-transcribed,
and ampli¢ed using primers 5P and 3P of the site of insertion
of variant exons. All samples showed a predominant PCR
product of about 320 kb, the size of CD44 standard.
Exon speci¢c analysis of Hl-60 cells without PMA showed a
rather constant expression of mRNA encoding CD44v6^
CD44v10. Hl-60 cells treated with PMA showed the same
CD44v expression pattern. 0 h, 12 h, 24 h, 36 h and 48 h,
this major variant chain consisting of CD44v6^10 was
present. There were no di¡erences in the splice pattern be-
tween the two groups. No splice variant was missing or over-
expressed. Fig. 6 shows the splice pattern of Hl-60 cells
treated with PMA for 36 h.
4. Discussion
CD44v6 seems to play an important role in tumor progres-
sion and is supposed to contribute to a high metastatic po-
tential [29^34]. We could recently show that CD44v6 is ex-
pressed in both, normal pancreas and pancreatic cancer [35],
and that, interestingly, sCD44s and sCD44v6 are signi¢cantly
reduced in pancreatic carcinoma patients compared to healthy
volunteers [36]. There, immunoprecipitation of human sera
with anti-CD44v6 revealed three CD44v6 isoforms ranging
between 90 kDa and 160 kDa, while in the supernatant of
pancreatic carcinoma cell lines, an isoform of 175 kDa could
be detected, which was abandoned in human sera. To deter-
mine whether sCD44s and sCD44v6 could be derived from
peripheral leukocytes, we performed in vitro culture of whole
blood. Based upon previous ¢ndings that CD44v6 is transi-
ently expressed on B and T lymphocytes following antigenic
stimulation, we used culture conditions that particularly stim-
ulate T cells. We have shown that in vitro culture of mono-
cytes is associated with increased cell surface expression of
CD44s and CD44v6 independent of a given treatment. 48 h
after stimulation with PHA, monocytes show a rapid decrease
of CD44v6 expression, whereas monocytes without treatment
or Il-2 show a slight increase. It is well known that CD44v6
expression shows a peak 24^48 h following activation and a
decline to baseline levels thereafter [26]. It could therefore be
possible that monocytes without mitogen or Il-2 show the
same kinetic later than 48 h of culture. Stimulation with
PHA and Il-2 could not upregulate cell surface expression
on T cells, B cells or natural killer cells. It has been shown
that in vitro culture of PB monocytes in the presence of hu-
man serum induces monocytes, but not T and B lymphocytes,
to bind HA and upregulate monocyte expression of high mo-
lecular weight CD44v isoforms [27]. Interestingly, culture of
whole blood without any stimulus served as a trigger to up-
regulate CD44v6 on monocytes. These results suggest that
CD44v6 plays an important role in monocytes di¡erentiating
into macrophages. To further investigate which subset of leu-
Fig. 5. Western blot analysis of CD44v6 in Hl-60 cells in the absence (control) or presence of PMA for 0, 12, 24, 36 and 48 h. Cells were lysed
and boiled in SDS gel sample bu¡er. 20 Wg of protein was run on 10% polyacrylamide gels and transferred to nitrocellulose. Blots incubated
with anti-CD44v6 antibodies and developed with biotinylated rabbit anti-mouse polyclonal serum. Binding of antibodies was detected using
Western-Light system (Tropix).
Fig. 6. Exon speci¢c analysis of Hl-60 cells stimulated with PMA
for 36 h. After RT, exon speci¢c PCR was performed using primers
located on the 5P side of the constant region (C13A) or the variant
exons (v2^v10). From the size and the presence of the splice prod-
ucts, the chain compositions can be concluded as described recently
[32]. No splice product was overexpressed or missing, compared to
untreated control cells.
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kocytes is associated with increased levels of CD44v6, we used
the promyelocytic cell line Hl-60 as a model for leukocyte
di¡erentiation. Addition of DMSO increases spontaneous dif-
ferentiation of Hl-60 cells to granulocytes, with most cells
acquiring morphological, functional, enzymatic and surface
membrane antigen characteristics of mature granulocytes
[37]. The phorbol ester PMA induces a macrophage-like phe-
notype. Several important phenotypic characteristics clearly
distinguish the Hl-60 macrophage-like di¡erentiation from
Hl-60 monocytic di¡erentiation induced by vitamin D3 and
Q-interferon. Macrophage-like Hl-60 cells are markedly more
adherent than Hl-60 monocytes, and do not have several spe-
ci¢c surface antigens present on normal and Hl-60 monocytes
[38,39]. An important role of CD44v6 and CD44v9 in in£am-
mation has been described, suggesting that CD44v expression
is associated with di¡erentiation of monocytes to tissue mac-
rophages in vivo. It is possible, therefore, that changes in cell
surface CD44v6 expression are not only important factors
controlling di¡erentiation of monocytes but also of granulo-
cytes and macrophages. We have clearly demonstrated upreg-
ulation of CD44v6 isoform expression in Hl-60 cells di¡er-
entiating to macrophages but not in cells di¡erentiating to
monocytes or granulocytes. Our data raise the hypothesis
that only macrophage di¡erentiation of the lineage di¡eren-
tiation experiments shown here may be associated with in-
creased expression of CD44v6 isoform. Interestingly, un-
treated cells and cells treated with DMSO, vitamin D3 or
interferon showed the same basal increasing expression for
CD44v6. CD44v6 on the cell surface was slightly upregulated
between 12 and 24 h. After 36 h, CD44v6 was decreasing. One
possible explanation for this e¡ect is that about 5% of the Hl-
60 cells exhibit spontaneous di¡erentiation to morphological
mature cells. This percentage may be increased by addition of
serum to media. Analysis of cultured monocytes has demon-
strated that in vitro monocyte culture in the presence of serum
promotes di¡erentiation of monocytes into tissue macro-
phages [38]. Our results from Western blot and PCR indicate
that high molecular CD44v isoforms are not only expressed
after treatment with PMA but also in untreated control cells.
PCR revealed that the mRNA is constantly transcribed inde-
pendent of a given treatment. Furthermore, protein levels of
CD44v6 in untreated control cells are markedly high,
although we found hardly any expression of the protein on
the cell surface. These results suggest that CD44 in our system
is transcribed constantly, spliced to speci¢c isoforms, includ-
ing CD44v6, which might be stored intracellularly and only be
translocated to the cell surface in cases of macrophage-like
di¡erentiation.
Langerhans cells and dendritic cells upregulate variant
exons v4, v5, v6 and v9 upon antigen contact. These splice
variants are obligatory for the migration and function of
Langerhans cells and dendritic cells [5,6]. In the view of tissue
migration, macrophages, dendritic cells, Langerhans cells and
metastatic tumor cells share several similarities. All these cell
types have to be able to migrate tissue and keep motility.
CD44v6 was ¢rst described in metastasizing rat pancreatic
carcinoma cell line, while non-metastasizing tumor cell line
or most normal rat tissues show no expression. This meta-
static potential could be conferred to non-metastasizing cells
[28]. Our results of whole blood stimulation showed only
macrophages to express CD44v6 on the cell surface. There-
fore, one could think that CD44v6 surface expression is a
common feature of macrophages and macrophage-like di¡er-
entiated cells. Based on this assumption, it could be possible
that CD44v6 enables not only macrophages but also tumor
cells to migrate and move in the tissue and therefore is a
prognostic factor of tumor progression and metastasis at least
in some tumors.
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